MERK Stock Overview
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia.
Price History & Performance
|Historical stock prices|
|Current Share Price||Rp3,730.00|
|52 Week High||Rp4,100.00|
|52 Week Low||Rp3,090.00|
|1 Month Change||-0.27%|
|3 Month Change||-7.90%|
|1 Year Change||16.20%|
|3 Year Change||-7.21%|
|5 Year Change||-59.89%|
|Change since IPO||1,244.15%|
Recent News & Updates
|MERK||ID Pharmaceuticals||ID Market|
Return vs Industry: MERK exceeded the ID Pharmaceuticals industry which returned 0.5% over the past year.
Return vs Market: MERK matched the ID Market which returned 15.6% over the past year.
|MERK Average Weekly Movement||2.5%|
|Pharmaceuticals Industry Average Movement||3.7%|
|Market Average Movement||6.3%|
|10% most volatile stocks in ID Market||12.0%|
|10% least volatile stocks in ID Market||3.0%|
Stable Share Price: MERK is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: MERK's weekly volatility (3%) has been stable over the past year.
About the Company
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. The company operates in the healthcare, life science, and performance materials sectors.
Merck Fundamentals Summary
|MERK fundamental statistics|
Is MERK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MERK income statement (TTM)|
|Cost of Revenue||Rp665.71b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||293.89|
|Net Profit Margin||12.37%|
How did MERK perform over the long term?See historical performance and comparison
3.3%Current Dividend Yield
Is Merck undervalued compared to its fair value and its price relative to the market?
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MERK (IDR3730) is trading below our estimate of fair value (IDR24475.66)
Significantly Below Fair Value: MERK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MERK is good value based on its PE Ratio (12.7x) compared to the ID Pharmaceuticals industry average (20.9x).
PE vs Market: MERK is good value based on its PE Ratio (12.7x) compared to the ID market (18.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MERK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MERK's PB Ratio (2.4x) is in line with the ID Pharmaceuticals industry average.
How is Merck forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merck has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Merck performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MERK has high quality earnings.
Growing Profit Margin: MERK's current net profit margins (12.4%) are higher than last year (11%).
Past Earnings Growth Analysis
Earnings Trend: MERK's earnings have grown by 4.2% per year over the past 5 years.
Accelerating Growth: MERK's earnings growth over the past year (83.1%) exceeds its 5-year average (4.2% per year).
Earnings vs Industry: MERK earnings growth over the past year (83.1%) exceeded the Pharmaceuticals industry 12.8%.
Return on Equity
High ROE: MERK's Return on Equity (19.2%) is considered low.
How is Merck's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MERK's short term assets (IDR768.1B) exceed its short term liabilities (IDR282.9B).
Long Term Liabilities: MERK's short term assets (IDR768.1B) exceed its long term liabilities (IDR59.3B).
Debt to Equity History and Analysis
Debt Level: MERK is debt free.
Reducing Debt: MERK had no debt 5 years ago.
Debt Coverage: MERK has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MERK has no debt, therefore coverage of interest payments is not a concern.
What is Merck current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MERK's dividend (3.27%) is higher than the bottom 25% of dividend payers in the ID market (1.12%).
High Dividend: MERK's dividend (3.27%) is low compared to the top 25% of dividend payers in the ID market (4.17%).
Stability and Growth of Payments
Stable Dividend: MERK's dividend payments have been volatile in the past 10 years.
Growing Dividend: MERK's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (41.5%), MERK's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (43.1%), MERK's dividend payments are well covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Evie Yulin (54 yo)
Ms. Evie Yulin serves as President Director at PT Merck Tbk since January 2020. She served as a Business Unit Director of PT Astra Zeneca Indonesia and Marketing Director of PT Aventis Pharma (Sanofi Avent...
Experienced Management: MERK's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: MERK's board of directors are seasoned and experienced ( 11.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Merck Tbk's employee growth, exchange listings and data sources
- Name: PT Merck Tbk
- Ticker: MERK
- Exchange: IDX
- Founded: 1970
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp1.671t
- Shares outstanding: 448.00m
- Website: https://www.merckgroup.com/id-id
Number of Employees
- PT Merck Tbk
- Jl. TB Simatupang No. 8
- Pasar Rebo
- Jakarta Timur
- Jakarta Raya
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.